Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Photo of smiling main in suit against white background wall

Professor Paresh Vyas is one of eight Oxford researchers that have been elected to the Academy of Medical Sciences Fellowship.

The new Fellows have been elected to the Academy in recognition of their exceptional contributions to the advancement of biomedical and health science, cutting edge research discoveries, and translating developments into benefits for patients and wider society.

Professor Vyas is a Professor of Haematology and a Consultant Physician, whose research involves improving understanding of the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.

Professor Vyas said "I am delighted and honoured to be elected a Fellow of the Academy of Sciences that does so much good work for medicine and science. I have had the privilege of working with immensely talented and wonderful colleagues in the MRC WIMM, in Oxford and elsewhere; and this recognition would not have been possible without them. I also want to acknowledge the vibrant and rewarding environment of the MRC WIMM and Oxford, which makes all of this possible."

Many congratulations to Professor Vyas!

Read the full story on the Oxford University website.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with


Similar stories

Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies

Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on groundbreaking research from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford.